Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Delirium Prevention in End-of-Life Patients
NCT02536417Phase 3Completed
- Sponsor
- Fraser Health
- Start
- Jun 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melatonin in delirium, sponsored by Fraser Health. Started Jun 2016; status: completed.
02
Drugs
melatonin
03
Conditions
delirium
Beyond the preview
Go deeper on NCT02536417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536417.